Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 28;13:167. doi: 10.1186/s13148-021-01149-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — FKBP1B and PAX9 methylation analysis in primary tumors and survival analysis. A The methylation rates were evaluated in clinical samples from different cohorts through MSP (methylation-specific PCR). For each sample, the presence of a product in lane M was considered as methylated DNA, while the product amplification in lane U was considered as non-methylated. Negative and positive controls for each reaction corresponded to DNA from PBMCs and in vitro methylated DNA, respectively. Representative MSPs of candidate genes are shown. B Samples 78, 79, 80, 82 and 140 showed methylation for FKBP1B, C and samples 152, 153 and 155 showed methylation for PAX9. Kaplan–Meier comparison in terms of overall survival (OS) between cisplatin response and PAX9 methylation in 21 patients with platinum-resistant ovarian cancer treated. Qualitative and quantitative methylation comparisons correspond to D and E, respectively. Log-rank tests were used for comparisons, and p values < 0.05 indicated a significant change in OS. We employed a Kaplan–Meier plotter tool to compare PAX9 expression versus OS and progression-free survival (PFS) (F, G) in 505 and 475 selected TCGA patients, respectively. A log-rank test was applied for comparisons, and p values < 0.05 indicated a significant change in OS